Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901325 · ClinicalTrials.gov registry record · Phase 2
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A Phase 2 study of Wound Heal and Skin Diseases, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04901325: Completed Phase 2 study of Wound Heal and Skin Diseases, sponsored by Oregon Health and Science University.
NCT04901325 is a Phase 2 study of Wound Heal and Skin Diseases that has completed, run by Oregon Health and Science University. The registered enrollment target is 5 participants, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04901325, a Phase 2 study of Wound Heal and Skin Diseases, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
Primary Outcome
defined as the proportion of patients with complete re-epithelization, defined as 100% re-epithelialization without any drainage, of the target ulcer at week 24.
Conditions Studied
Interventions
- DRUG Baricitinib
Study Locations (1)
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 2 |
What the finished NCT04901325 record still lists
NCT04901325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 119-participant average among 23 other Wound Heal trials with a reported enrollment target (96% lower).
The record links to 5 conditions, with Wound Heal appearing as the primary indexed condition, and to 1 intervention - of which Baricitinib is the first listed.
NCT04901325 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT04901325 about?
NCT04901325 is a clinical study titled "Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)". An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
What is the current status of trial NCT04901325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2023-10-03. Estimated completion is 2025-05-07.
What conditions does trial NCT04901325 study?
This clinical trial studies the following conditions: Wound Heal, Skin Diseases, Skin Ulcer, Pyoderma Gangrenosum, Pyoderma.
What interventions are being tested in trial NCT04901325?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT04901325?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04901325 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wound Heal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04901325's enrollment target sits among peer trials
5 24th of 23 the lowest of 23 other Wound Heal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Wound Heal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
4-aminopyridine for Skin Wound Healing
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
COMPLETED · Phase 2
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Tissue Repair Gel in Venous Leg Ulcers in AU/US
RECRUITING · Phase 3
-
Dermabrasion in Mohs: Split-Scar Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI